sotalol/generics 80mg/tab tab
generics pharma hellas ΕΠΕ - sotalol - ΔΙΣΚΙΟ - 80mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
sotalol/generics 160mg/tab tab
generics pharma hellas ΕΠΕ - sotalol - ΔΙΣΚΙΟ - 160mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
novamune πυκνό σκεύασμα και διαλύτης για ενέσιμο εναιώρημα για ορνίθια
qi01ad09 - granted - ceva-phylaxia co. ltd - vaccine - chickens
gletvax 6, suspension for injection for piglets
qi09ab08 - granted - zoetis hellas s.a. - vitatrace nutrition ltd
pentaxim powder & suspension for suspension for injection
sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - diphtheria toxoid; poliomyelitis virus type 3; tetanus toxoid; pertussis toxoid(pt); filamentous haemagglutinin (fha); poliomyelitis virus type 2; poliomyelitis virus type 1; haemophilus infl. type b polys.conj.t.toxoid - powder & suspension for suspension for injection - diphtheria toxoid (8000000804) 0iu; poliomyelitis virus type 3 (8000000485) 32du; tetanus toxoid (8000040440) 0iu; pertussis toxoid(pt) (8000001811) 25mcg; filamentous haemagglutinin (fha) (8000001813) 25mcg; poliomyelitis virus type 2 (8000000484) 8du; poliomyelitis virus type 1 (8000000483) 40du; haemophilus infl. type b polys.conj.t.toxoid (8000001810) 10mcg - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus
ultomiris
alexion europe sas - ravulizumab - Αιμοσφαιρινουρία, παροξυσμική - Επιλεκτικά ανοσοκατασταλτικά - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
avaxim 160 antigen units/0.5ml suspension for injection in pre-filled syringe
sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - hepatitis a virus (gbm strain) inactivated - suspension for injection in pre-filled syringe - 160 antigen units/0.5ml - hepatitis a virus (gbm strain) inactivated (8000003025) 160u - hepatitis a, inactivated, whole virus
vigam liquid 5g/100ml solution for intravenous infusion
bio products laboratory limited (0000009242) dagger lane, elstree, hertfordshire, wd6 3bx - immunoglobulin human normal - solution for intravenous infusion - 5g/100ml - immunoglobulin human normal (8000012671) 5% w/v - immunoglobulins, normal human, for intravasc. adm.
nextmune πυκνό σκεύασμα και διαλύτης για παρασκευή ενέσιμου εναιωρήματος για ορνίθια
qi01ad09 - granted - ceva-phylaxia co. ltd - vaccine - panchris feeds (veterinary) ltd